IL327295A - GLP-1R agonists, pharmaceutical compositions containing them and their uses in the treatment of cardiometabolic and related diseases - Google Patents
GLP-1R agonists, pharmaceutical compositions containing them and their uses in the treatment of cardiometabolic and related diseasesInfo
- Publication number
- IL327295A IL327295A IL327295A IL32729526A IL327295A IL 327295 A IL327295 A IL 327295A IL 327295 A IL327295 A IL 327295A IL 32729526 A IL32729526 A IL 32729526A IL 327295 A IL327295 A IL 327295A
- Authority
- IL
- Israel
- Prior art keywords
- glp
- agonists
- pharmaceutical compositions
- same
- associated diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019082381 | 2019-04-12 | ||
| PCT/CN2020/084203 WO2020207474A1 (en) | 2019-04-12 | 2020-04-10 | Glp-1r agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL327295A true IL327295A (en) | 2026-05-01 |
Family
ID=72750961
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL327295A IL327295A (en) | 2019-04-12 | 2020-04-10 | GLP-1R agonists, pharmaceutical compositions containing them and their uses in the treatment of cardiometabolic and related diseases |
| IL287128A IL287128B1 (en) | 2019-04-12 | 2020-04-10 | GLP-1R agonists, pharmaceutical compositions containing them and their uses in the treatment of cardiometabolic and related diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL287128A IL287128B1 (en) | 2019-04-12 | 2020-04-10 | GLP-1R agonists, pharmaceutical compositions containing them and their uses in the treatment of cardiometabolic and related diseases |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10954221B2 (ja) |
| EP (1) | EP3953344A4 (ja) |
| JP (2) | JP7635145B2 (ja) |
| KR (2) | KR20260022470A (ja) |
| CN (1) | CN113853371B (ja) |
| AU (1) | AU2020256647B2 (ja) |
| BR (1) | BR112021020335A2 (ja) |
| CA (1) | CA3136375A1 (ja) |
| CL (1) | CL2021002649A1 (ja) |
| CO (1) | CO2021015060A2 (ja) |
| CR (1) | CR20210562A (ja) |
| CU (1) | CU20210083A7 (ja) |
| DO (1) | DOP2021000208A (ja) |
| EA (1) | EA202192684A1 (ja) |
| IL (2) | IL327295A (ja) |
| MA (1) | MA55627A (ja) |
| MX (1) | MX2021012492A (ja) |
| PE (1) | PE20220143A1 (ja) |
| PH (1) | PH12021552557A1 (ja) |
| SA (1) | SA521430550B1 (ja) |
| SG (1) | SG11202110825WA (ja) |
| UA (1) | UA130404C2 (ja) |
| WO (1) | WO2020207474A1 (ja) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20210042A7 (es) | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
| BR112021020335A2 (pt) | 2019-04-12 | 2021-12-14 | Qilu Regor Therapeutics Inc | Agonistas glp-1r e usos dos mesmos |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| PE20221040A1 (es) * | 2019-10-25 | 2022-06-17 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| EP4069686B1 (en) * | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| CA3168543A1 (en) * | 2020-01-29 | 2021-08-05 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| PE20231066A1 (es) | 2020-02-07 | 2023-07-17 | Gasherbrum Bio Inc | Agonistas heterociclicos de glp-1 |
| JP7836762B2 (ja) * | 2020-02-13 | 2026-03-27 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| MX2022011349A (es) * | 2020-03-18 | 2022-11-10 | Lg Chemical Ltd | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| EP4143183B1 (en) | 2020-04-29 | 2025-10-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2021259309A1 (zh) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| WO2022028572A1 (en) | 2020-08-06 | 2022-02-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN116406360A (zh) | 2020-08-28 | 2023-07-07 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| JP7858636B2 (ja) | 2020-09-10 | 2026-05-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| WO2022068772A1 (zh) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN116348464A (zh) | 2020-10-12 | 2023-06-27 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| CN116547279A (zh) * | 2020-10-13 | 2023-08-04 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2022078352A1 (en) * | 2020-10-14 | 2022-04-21 | Qilu Regor Therapeutics Inc. | Crystal forms of glp-1r agonists and uses thereof |
| CN114478497B (zh) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | 芳基烷基酸类glp-1受体激动剂及其用途 |
| WO2022109182A1 (en) * | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| CA3200245A1 (en) * | 2020-11-27 | 2022-06-02 | Junjun Wu | Benzimidazole derivative and preparation method therefor and medical use thereof |
| CN112516168B (zh) * | 2020-12-11 | 2022-07-26 | 中国人民解放军军事科学院军事医学研究院 | 用于干预应激性认知障碍的间充质干细胞 |
| US20220193063A1 (en) * | 2020-12-15 | 2022-06-23 | Pfizer Inc. | Metabolites of glp1r agonists |
| AU2021405918A1 (en) * | 2020-12-25 | 2023-07-20 | Xizang Haisco Pharmaceutical Co., Ltd. | Five-membered ring derivative and medical use thereof |
| CN114805336B (zh) * | 2021-01-20 | 2026-04-14 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类化合物、其制备方法及其在医药上的应用 |
| MX2023008854A (es) | 2021-01-28 | 2023-10-17 | Carmot Therapeutics Inc | Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso. |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| EP4304711A1 (en) * | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022192430A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| CN116940561A (zh) * | 2021-03-22 | 2023-10-24 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
| US20220348564A1 (en) * | 2021-03-24 | 2022-11-03 | Eccogene (Shanghai) Co., Ltd. | Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same |
| JP7772778B2 (ja) | 2021-03-24 | 2025-11-18 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| EP4303215A4 (en) * | 2021-04-08 | 2024-09-18 | Lg Chem, Ltd. | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING IT AND PREPARATION METHOD THEREOF |
| JP2024514259A (ja) * | 2021-04-08 | 2024-03-29 | エルジー・ケム・リミテッド | Ｇｌｐ－１受容体作動薬、それを含む薬学的組成物、およびその製造方法 |
| KR20230170034A (ko) * | 2021-04-12 | 2023-12-18 | 노파르티스 아게 | 비만 치료를 위한 glp1 수용체의 활성화제로서의 2-((4-((s)-2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]디옥솔-4-일)피페리딘-1-일)메틸)-1-(((s)-옥세탄-2-일)메틸)-1h-이미다졸 유도체 |
| PL4271672T3 (pl) | 2021-04-21 | 2026-04-20 | Gilead Sciences, Inc. | Karboksybenzimidazolowe związki modulujące glp-1r |
| CN117279905A (zh) * | 2021-04-21 | 2023-12-22 | 吉利德科学公司 | 羧基-苯并咪唑glp-1r调节化合物 |
| PE20232051A1 (es) * | 2021-04-21 | 2023-12-27 | Gilead Sciences Inc | Compuestos carboxi-benzimidazol moduladores de glp-1r |
| CN117295729A (zh) * | 2021-04-21 | 2023-12-26 | 吉利德科学公司 | 羧基-苯并咪唑glp-1r调节化合物 |
| EP4334304A1 (en) * | 2021-05-03 | 2024-03-13 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| TWI843104B (zh) * | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CN117355517A (zh) * | 2021-05-20 | 2024-01-05 | 伊莱利利公司 | 大环胰高血糖素样肽1受体激动剂 |
| MX2023014985A (es) * | 2021-06-24 | 2024-02-14 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Agonista del receptor de glp-1 y composicion y uso del mismo. |
| JP2024525900A (ja) * | 2021-07-21 | 2024-07-12 | ヘパジーン セラピューティクス（エイチケー）リミティド | グルカゴン様ペプチド－１受容体モジュレーター及びその使用 |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| US20240360109A1 (en) * | 2021-08-04 | 2024-10-31 | Shanghai Hansoh Biomedical Co., Ltd. | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
| WO2023029380A1 (zh) | 2021-08-30 | 2023-03-09 | 杭州德睿智药科技有限公司 | 作为glp1r激动剂的新型芳醚取代杂环类化合物 |
| AU2022344074A1 (en) | 2021-09-08 | 2024-02-29 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| FI4408840T3 (fi) | 2021-09-27 | 2025-11-04 | Terns Pharmaceuticals Inc | Bentsimidatsolikarboksyylihappoja glp-1r-agonisteina |
| EP4412707A1 (en) | 2021-10-05 | 2024-08-14 | Astrazeneca AB | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| IL312364A (en) | 2021-10-25 | 2024-06-01 | Luehr Gary W | Compounds as GLP-1R agonists |
| EP4441047A4 (en) * | 2021-12-03 | 2025-03-19 | Hangzhou Sciwind Biosciences Co., Ltd. | CRYSTALLINE FORMS OF THIENOIMIDAZOLE COMPOUND AND PROCESS FOR THEIR PREPARATION |
| JPWO2023106310A1 (ja) * | 2021-12-07 | 2023-06-15 | ||
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN116354945B (zh) * | 2021-12-27 | 2024-08-30 | 长春金赛药业有限责任公司 | 一种稠合咪唑羧酸类化合物及其制备方法和应用 |
| WO2023130878A1 (zh) * | 2022-01-10 | 2023-07-13 | 海思科医药集团股份有限公司 | 一种glp-1激动剂盐及其晶型及在医药上的应用 |
| US12410163B2 (en) | 2022-02-23 | 2025-09-09 | Terns Pharmaceuticals, Inc. | Compounds as GLP-IR agonists |
| WO2023164358A1 (en) * | 2022-02-28 | 2023-08-31 | Ascletis Bioscience Co., Ltd. | Glp-1r modulating compounds |
| US20230271949A1 (en) * | 2022-02-28 | 2023-08-31 | Ascletis Bioscience Co., Ltd. | Glp-1r modulating compounds |
| CA3245508A1 (en) | 2022-03-08 | 2025-01-22 | Guangzhou Unirise Pharmaceutical Co., Ltd. | BENZO BICYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS APPLICATION |
| WO2023222084A1 (zh) * | 2022-05-20 | 2023-11-23 | 成都地奥九泓制药厂 | 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用 |
| WO2023246839A1 (zh) * | 2022-06-23 | 2023-12-28 | 西藏海思科制药有限公司 | 一种噻吩[2,3-d]咪唑类化合物的盐及其晶型和在医药上的用途 |
| CN117362282B (zh) * | 2022-07-07 | 2026-04-21 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| CN120379988A (zh) * | 2022-08-24 | 2025-07-25 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| MX2025002598A (es) * | 2022-09-06 | 2025-05-02 | Mindrank Therapeutics Suzhou New Drug Res And Development Co Ltd | Polimorfo de compuesto agonista de glp-1r, método de preparación para el mismo, y uso de este |
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| KR20250105662A (ko) * | 2022-11-11 | 2025-07-08 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| EP4619098A1 (en) | 2022-11-16 | 2025-09-24 | Eli Lilly and Company | Glucagon-like peptide 1 receptor agonists |
| WO2024125442A1 (zh) * | 2022-12-13 | 2024-06-20 | 杭州中美华东制药有限公司 | Glp-1受体激动剂的新晶型和制备方法及其药物组合物和用途 |
| CN116082321B (zh) * | 2022-12-23 | 2026-05-05 | 华中药业股份有限公司 | 一种咪唑并芳杂基类衍生物、药物组合物及其应用 |
| CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
| IL322686A (en) | 2023-02-16 | 2025-10-01 | Gasherbrum Bio Inc | Heterocyclic glp-1 agonists |
| WO2024211898A1 (en) | 2023-04-07 | 2024-10-10 | Terns Pharmaceuticals, Inc. | Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| AU2024340407A1 (en) | 2023-09-14 | 2026-04-23 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| KR20250125490A (ko) * | 2024-02-14 | 2025-08-22 | 주식회사 종근당 | Glp-1 수용체 작용제 및 이의 용도 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| JP2006525366A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 複素環式カルボン酸置換基 |
| NZ553696A (en) | 2004-09-13 | 2010-02-26 | Ono Pharmaceutical Co | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| AU2005307718A1 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids for the treatment of diabetes |
| EP1976873A2 (en) | 2006-01-11 | 2008-10-08 | Brystol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
| KR101616737B1 (ko) | 2008-03-07 | 2016-05-02 | 브이티브이 테라퓨틱스 엘엘씨 | 당뇨병 치료를 위한 옥사디아조안트라센 화합물 |
| US8765920B2 (en) | 2009-12-23 | 2014-07-01 | The Scripps Research Institute | Tyrosine bioconjugation through aqueous Ene-like reactions |
| NZ603876A (en) | 2010-05-13 | 2015-02-27 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| JP2013530963A (ja) | 2010-06-09 | 2013-08-01 | レセプトス インコーポレイテッド | 新規のｇｌｐ−１受容体安定化薬および調節薬 |
| MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| ES2836973T3 (es) | 2011-12-12 | 2021-06-28 | Receptos Llc | Derivados de ácido carboxílico que comprenden cuatro ciclos que actúan como moduladores de receptor GLP-1 para la terapia de enfermedades tales como la diabetes |
| PL3240785T3 (pl) | 2014-12-29 | 2021-12-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| CN110325530B (zh) * | 2016-12-16 | 2022-01-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| SG11202011704XA (en) * | 2018-06-15 | 2020-12-30 | Pfizer | Glp-1 receptor agonists and uses thereof |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| BR112021003039A2 (pt) | 2018-08-31 | 2021-05-18 | Pfizer Inc. | combinações para o tratamento de nash/nafld e doenças relacionadas |
| CU20210042A7 (es) | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
| BR112021020335A2 (pt) | 2019-04-12 | 2021-12-14 | Qilu Regor Therapeutics Inc | Agonistas glp-1r e usos dos mesmos |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| PE20221040A1 (es) * | 2019-10-25 | 2022-06-17 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| EP4069686B1 (en) * | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| WO2021116874A1 (en) | 2019-12-10 | 2021-06-17 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| CA3168543A1 (en) | 2020-01-29 | 2021-08-05 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| PE20231066A1 (es) | 2020-02-07 | 2023-07-17 | Gasherbrum Bio Inc | Agonistas heterociclicos de glp-1 |
| JP7836762B2 (ja) * | 2020-02-13 | 2026-03-27 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| IL296694A (en) | 2020-03-27 | 2022-11-01 | Pfizer | Treatment of type 2 diabetes, obesity or excess weight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[( 2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or its pharmaceutical salts |
| EP4141008A4 (en) | 2020-04-01 | 2024-04-17 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR |
| JP2023528565A (ja) | 2020-04-01 | 2023-07-05 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法 |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| CN113493447B (zh) | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
-
2020
- 2020-04-10 BR BR112021020335A patent/BR112021020335A2/pt unknown
- 2020-04-10 WO PCT/CN2020/084203 patent/WO2020207474A1/en not_active Ceased
- 2020-04-10 EA EA202192684A patent/EA202192684A1/ru unknown
- 2020-04-10 CR CR20210562A patent/CR20210562A/es unknown
- 2020-04-10 PH PH1/2021/552557A patent/PH12021552557A1/en unknown
- 2020-04-10 MX MX2021012492A patent/MX2021012492A/es unknown
- 2020-04-10 SG SG11202110825WA patent/SG11202110825WA/en unknown
- 2020-04-10 MA MA055627A patent/MA55627A/fr unknown
- 2020-04-10 KR KR1020267001628A patent/KR20260022470A/ko active Pending
- 2020-04-10 CU CU2021000083A patent/CU20210083A7/es unknown
- 2020-04-10 JP JP2021560022A patent/JP7635145B2/ja active Active
- 2020-04-10 IL IL327295A patent/IL327295A/en unknown
- 2020-04-10 AU AU2020256647A patent/AU2020256647B2/en active Active
- 2020-04-10 CA CA3136375A patent/CA3136375A1/en active Pending
- 2020-04-10 EP EP20788321.6A patent/EP3953344A4/en active Pending
- 2020-04-10 KR KR1020217036543A patent/KR102915918B1/ko active Active
- 2020-04-10 UA UAA202106216A patent/UA130404C2/uk unknown
- 2020-04-10 CN CN202080028229.XA patent/CN113853371B/zh active Active
- 2020-04-10 PE PE2021001694A patent/PE20220143A1/es unknown
- 2020-04-10 IL IL287128A patent/IL287128B1/en unknown
- 2020-06-16 US US16/902,807 patent/US10954221B2/en active Active
- 2020-11-17 US US16/950,393 patent/US11591321B2/en active Active
-
2021
- 2021-10-08 CL CL2021002649A patent/CL2021002649A1/es unknown
- 2021-10-11 SA SA521430550A patent/SA521430550B1/ar unknown
- 2021-10-11 DO DO2021000208A patent/DOP2021000208A/es unknown
- 2021-11-08 CO CONC2021/0015060A patent/CO2021015060A2/es unknown
-
2023
- 2023-02-24 US US18/113,859 patent/US20230278991A1/en not_active Abandoned
-
2024
- 2024-09-10 US US18/830,194 patent/US20250042883A1/en active Pending
-
2025
- 2025-02-10 JP JP2025019723A patent/JP2025072577A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287128B1 (en) | GLP-1R agonists, pharmaceutical compositions containing them and their uses in the treatment of cardiometabolic and related diseases | |
| IL283754A (en) | Anti-claudin antibodies, preparations containing them and their uses | |
| IL285782A (en) | Compounds, compositions, and methods for treating disease | |
| IL285651A (en) | Anti-trem2 antibodies, preparations containing them and their uses | |
| WO2017136450A3 (en) | Compounds and methods of treating rna-mediated diseases | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| HK1255162A1 (zh) | 爱帕琳肽受体激动剂及使用方法 | |
| HK1251482A1 (zh) | 用於治疗补体介导的疾病的组合物和方法 | |
| SG11202105540YA (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
| IL289932A (en) | History of 6,3-diamino-pyridazin-3-yl, pharmaceutical preparations containing them and their use as pro-apoptotic agents | |
| ZA202105586B (en) | Pharmaceutical delivery compositions and uses thereof | |
| MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
| MX2017010883A (es) | Composicion para el tratamiento de la infertilidad. | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| IL272767B1 (en) | A preparation containing Wharton gel, a method for its preparation and its uses | |
| EP4331622A3 (en) | Integrin binding peptides and uses thereof | |
| IL268997A (en) | Preparations containing agonists for the PGI2 receptor and processes for their preparation | |
| EP3275450A4 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis | |
| IL284765A (en) | 8,1-naphthyridinone compounds and their uses | |
| EP3792276A4 (en) | NOVEL FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION TO PREVENT OR TREAT CANCER THEREOF | |
| EP3246037A4 (en) | Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease | |
| GB201915831D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| SG11202104371XA (en) | 1,3,4-oxadiazolone compound and pharmaceutical |